7th November 2025
Annual Fred Heatley Meeting
Chatham Historic Dockyard
MagnetOs™ Bone Graft for Extremities: Advancing Orthobiological Innovation
Features
- Predictable fusion outcomes for reliable surgical results.†1-6
- Advanced NeedleGrip™ technology for optimal bone growth.†1-6
- Safe, and free from animal- or human-derived materials.7
MagnetOs™ Bone Graft provides an innovative approach for achieving reliable fusions and reconstructions in extremity surgeries. As a state-of-the-art bone graft equipped with NeedleGrip™ submicron surface technology, MagnetOs stands out for its demonstrated effectiveness, consistency, and ability to enhance results while improving operational efficiency for surgeons specialising in extremities.
- Proven through Level I clinical trials in humans
- Designed for predictable performance in extremity applications
- Powered by advanced NeedleGrip™ technology to promote bone formation
Key Features
- Innovative Surface Technology: NeedleGrip™ submicron features that leverage the body’s immune response for superior bone growth without additional cells or growth factors.
- Versatile Formulations: Available in various ready-to-use options to suit different extremity procedures and handling needs.
- Reliable Handling: Engineered to remain stable under challenges like joint compression, irrigation, and potential leakage common in extremity surgeries.
- Clinical Excellence: Backed by high-level evidence showing enhanced fusion rates compared to traditional autograft methods.
- Optimised for Outcomes: Supports efficient surgical workflows and improved healing, especially in complex cases such as those involving smokers.
Function of MagnetOs Bone Graft for Extremities
MagnetOs™ Bone Graft is tailored to address the specific demands of extremity fusions and reconstructions. It utilises its unique surface properties to stimulate natural bone regeneration, ensuring stability and predictability in areas prone to mechanical stress and fluid exposure.
Mechanism of Action
MagnetOs™ harnesses osteoimmunology principles to drive bone formation through immune system modulation:
- Polarize: Monocytes respond to the NeedleGrip™ surface by differentiating into pro-healing M2 macrophages, favoring regeneration over inflammation.
- Regenerate: These M2 macrophages activate stem cells to facilitate new bone tissue development.
- Propagate: The process sustains ongoing bone growth, leading to robust and consistent fusions without scar tissue formation.
MagnetOs Clinical Evidence for Extremities
MagnetOs™ is validated by top-tier Level I human clinical research, demonstrating nearly double the fusion success rate compared to autograft (79% vs. 47%) in spinal applications, with even greater advantages in challenging patient groups like smokers. This evidence extends to extremity uses through a comprehensive mix of peer-reviewed studies, preclinical data, and clinical outcomes via Project Fusion – a dedicated global initiative combining scientific rigor with real-world results.
For more details on the extensive supporting studies, visit the Project Fusion resource.
Interested in MagnetOs?
If you would like more information regarding MagnetOs Contact Us
Interested in the MagnetOs™ Bone Graft for Extremities: Advancing Orthobiological Innovation?
Get in touch with our experts today to learn more
Kuros Biosciences is at the forefront of innovation in orthopaedic solutions, dedicated to advancing patient care through groundbreaking scientific research and development. As the inventors of MagnetOs, Kuros Biosciences leverages extensive expertise in osteoimmunology to deliver products that redefine standards in bone graft technology. With a commitment to evidence-based solutions, Kuros continues to set benchmarks in clinical excellence and patient outcomes.
LEDA Orthopaedics is proud to partner with Kuros Biosciences to bring MagnetOs to trauma and orthopaedic clinicians in the UK. With a focus on exceptional service to both the NHS and the independent sector, LEDA supports surgeons and their teams with the tools they need to achieve superior patient outcomes, combining global innovation with local expertise.
†Results from in vivo or in vitro laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com
MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
- Duan, et al. eCM. 2019;37:60-73.
- Van Dijk, et al. eCM. 2021;41:756-73.
- Van Dijk, et al. JOR Spine. 2018;e1039
- Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
- Van Dijk, et al. Clin Spine Surg. 2019;33(6):E276-E287.
- Stempels, et al. Spine. 2024;49(19):1323-1331
- Instructions for Use (IFU) MagnetOs Putty (EU).
- Fusco
- Liguori, et al. Cell Mol Immunol. 2021;18(3):711–722.
- Zhang, et al. Cell Tissue Res. 2017.
- Arosarena, et al. J Cell Physiol. 2011;226(11):2943–2952
Frequently Asked Questions
MagnetOs employs NeedleGrip™ submicron surface technology to direct immune responses toward pro-healing pathways, enhancing bone formation in extremity reconstructions.
It is backed by Level I studies showing superior fusion rates over autograft, with additional preclinical and peer-reviewed data available through Project Fusion.
Available in granules, putty, and mix formats, it offers flexible handling to meet various surgical needs in the extremities.
MagnetOs products are shelf-stable at room temperature with a multi-year shelf life; refer to specific IFUs for details.
It is a biphasic calcium phosphate graft with no added biologics, relying on its surface technology for efficacy.